Abstract 2047P
Background
Despite significant advances in prevention and treatment, febrile neutropenia (FN) remains a common and serious complication of chemotherapy. Leverages data related to G-CSF use are missing. This study aims to (1) describe the practices of G-CSF treatment implementation; (2) identify and measure the decision criteria related to their implementation in patients with breast (BC), lung (LC), or gastrointestinal cancers (GIC), in ambulatory settings, beyond the usual recommendations.
Methods
This non-interventional, cross-sectional, multicenter study required clinical cases presented using conversational interfaces (chatbot), simulating a conversation with one or several virtual interlocutors by voice or text exchange.
Results
The questionnaire was completed by 102 physicians. Most practitioners (84.5%) reported prescribing G-CSF, regardless of tumor type (Table). G-CSF was prescribed more frequently for adjuvant/neoadjuvant therapy than for metastatic cases. Leading factors motivating the prescription were chemotherapy regimen, comorbidities, and age (in 56.7% of cases). Access to care was cited as a reason to prescribe G-CSF.
Table: 2047P
Levels and reasons of G-CSF prescription in all 3 cancer types
Breast cancer | Lung cancer | Gastro Intestinal cancer | Total | ||
Implementation of a G-CSF treatment N (%) | N | 77 | 57 | 60 | 194 |
Yes | 68 (88.3%) | 42 (73.7%) | 54 (90.0%) | 164 (84.5%) | |
Not | 9 (11.7%) | 15 (26.3%) | 6 (10.0%) | 30 (15.5%) | |
What should be considered before prescribing a G-CSF for this patient? N (%) | N | 68 | 42 | 54 | 164 |
Chemotherapy Protocol | 23 (33.8%) | 9 (21.4%) | 7 (13.0%) | 39 (23.8%) | |
Chemotherapy Protocol + comorbidities | 12 (17.6%) | 2 (4.8%) | 8 (14.8%) | 22 (13.4%) | |
Chemotherapy Protocol + Age | 2 (2.9%) | 6 (14.3%) | 2 (3.7%) | 10 (6.1%) | |
Chemotherapy Protocol + comorbidities + age | 31 (45.6%) | 25 (59.5%) | 37 (68.5%) | 93 (56.7%) |
Conclusions
Our findings suggest that ESMO recommendations are broadly followed. In most cases, G-CSF is prescribed in early stages and in curative intent. Despite a large use of G-CSF, education about febrile neutropenia and risk factors should be disseminated to a wide audience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Viatris.
Funding
Viatris.
Disclosure
F. Scotté: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Pierre Fabre Oncology, MSD, Amgen, Helsinn, BMS, Pfizer, Thermo Fisher, Alliance Healthcare, Biogaran, Sandoz, Sanofi, Pharmanovia, Viatris.
Resources from the same session
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06